Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients?

International Journal of Antimicrobial Agents

Volumn 32, Issue SUPPL. 2, 2008, Pages

  Salavert, Miguel ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Empirical therapy; Non lung transplant patients; Pre emptive therapy; Prophylaxis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CALCINEURIN INHIBITOR; CASPOFUNGIN; CLOTRIMAZOLE; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; NYSTATIN; PLACEBO; POSACONAZOLE; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE INHIBITOR; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIGEN DETECTION; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HEART LUNG TRANSPLANTATION; HEART TRANSPLANTATION; HUMAN; INTESTINE TRANSPLANTATION; INVASIVE CANDIDIASIS; KIDNEY FAILURE; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOADING DRUG DOSE; MORBIDITY; MORTALITY; MYCOSIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; CHEMOPREVENTION; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; TRANSPLANTATION;

EID: 55649086380     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(08)70017-7     Document Type: Article

References (41)

1. Singh N. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. Clin Infect Dis 39 Suppl 4 (2004) S200-S206
2. Marik P.E. Fungal infections in solid organ transplantation. Expert Opin Pharmacother 7 (2006) 297-305
3. Solé A., and Salavert M. Voriconazole for the therapy of mycoses in recipients of solid organ transplants [in Spanish]. Rev Iberoam Micol 24 (2007) 217-222
4. Silveira F.P., and Husain S. Fungal infections in solid organ transplantation. Med Mycol 45 (2007) 305-320
5. Solé A., Morant P., Salavert M., Pemán J., Morales P., and Valencia Lung Transplant Group. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 11 (2005) 359-365
6. Singh N., and Paterson D.L. Aspergillus infections in transplant recipients. Clin Microbiol Rev 18 (2005) 44-69
7. Solé A, Salavert M. Fungal infections after lung transplantation. Transplant Rev Forthcoming 2008.
8. Singh N. Invasive aspergillosis in organ transplant recipients: new issues in epidemiologic characteristics, diagnosis, and management. Med Mycol 43 Suppl 1 (2005) S267-S270
9. Singh N., Alexander B.D., Lortholary O., et al., Cryptococcal Collaborative Transplant Study Group. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 195 (2007) 756-764
10. Metcalf S.C., and Dockrell D.H. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. J Infect 55 (2007) 287-299
11. van Burik J.A. Role of new antifungal agents in prophylaxis of mycoses in high risk patients. Curr Opin Infect Dis 18 (2005) 479-483
12. Bow E.J. Considerations in the approach to invasive fungal infection in patients with haematological malignancies. Br J Haematol 140 (2008) 133-152
13. Leather H.L., and Wingard J.R. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies. Blood Rev 20 (2006) 267-287
14. Echániz-Quintana A., Pita-Fernández S., Otero-Ferreiro A., Suárez-López F., Gómez-Gutiérrez M., and Guerrero-Espejo A. Risk factors associated with invasive fungal infection in orthotopic liver transplantation. Med Clin (Barc) 122 (2004) 444-448
15. Singh N., Limaye A.P., Forrest G., et al. Late-onset invasive aspergillosis in organ transplant recipients in the current era. Med Mycol 44 (2006) 445-449
16. Singh N., Pruett T.L., Houston S., et al. Invasive aspergillosis in the recipients of liver retransplantation. Liver Transpl 12 (2006) 1205-1209
17. Hellinger W.C., Bonatti H., Yao J.D., et al. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation. Liver Transpl 11 (2005) 656-662
18. Castroagudín J.F., Pontón C., Bustamante M., et al. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Transplant Proc 37 (2005) 3965-3967
19. Playford E.G., Webster A.C., Sorell T.C., and Craig J.C. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev 3 (2004) CD004291.
20. Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis 31 (2000) 545-553
21. Hellinger W.C., Yao J.D., Alvarez S., et al. A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation. Transplantation 73 (2002) 1904-1909
22. Arnow P.M., Carandang G.C., Zabner R., and Irwin M.E. Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation. Clin Infect Dis 22 (1996) 997-1003
23. Hjortrup A., Rasmussen A., Hansen B.A., et al. Early bacterial and fungal infections in liver transplantation after oral selective bowel decontamination. Transplant Proc 29 (1997) 3106-3110
24. Wiesner R.H., Hermans P.E., Rakela J., et al. Selective bowel decontamination to decrease Gram-negative aerobic bacterial and Candida colonization and prevent infection after orthotopic liver transplantation. Transplantation 45 (1988) 570-574
25. Lumbreras C., Cuervas-Mons V., Jara P., et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 174 (1996) 583-588
26. Winston D.J., Pakrasi A., and Busuttil R.W. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo controlled trial. Ann Intern Med 131 (1999) 729-737
27. Sharpe M.D., Ghent C., Grant D., et al. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation 76 (2003) 977-983
28. Cruciani M., Mengoli C., Malena M., Bosco O., Serpelloni G., and Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 12 (2006) 850-858
29. Husain S., Tollemar J., Dominguez E.A., et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 75 (2003) 2023-2029
30. Singh N., Paterson D.L., Gayowski T., Wagener M.M., and Marino I.R. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 71 (2001) 910-913
31. Fortun J., Martin-Davila P., Moreno S., et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 52 (2003) 813-819
32. Tollemar J., Hockerstedt K., Ericzon B.G., Jalanko H., and Ringden O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation 59 (1995) 45-50
33. Winston D.J., and Busuttil R.W. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 74 (2002) 688-695
34. Fortún J, Montejo M, Martín-Dávila P, et al.; Spanish Transplantation Infection Study Group. Prospective, multicentre study of caspofungin for prophylaxis in high-risk liver transplantation. In: 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 31 March-4 April 2007; Munich, Germany, p. S254. Abstract P965.
35. Kontoyiannis D.P., Lewis R.E., Osherov N., Albert N.D., and May G.S. Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother 51 (2003) 313-316
36. Singh N., Wagener M.M., Cacciarelli T.V., and Levitsky J. Antifungal management practices in liver transplant recipients. Am J Transplant 8 (2008) 426-431
37. Biancofiore G., Bindi M.L., Baldassarri R., et al. Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study. Transpl Int 15 (2002) 341-347
38. Munoz P., Rodríguez C., Bouza E., et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant 4 (2004) 636-643
39. Perkins J.D. Use of Aspergillus galactomannan enzyme-linked immunosorbent assay (ELISA) in liver transplant patients. Liver Transpl 13 (2007) 304-305
40. Akamatsu N., Sugawara Y., Kaneko J., Tamura S., and Makuuchi M. Preemptive treatment of fungal infection based on plasma (1→3)-β-D-glucan levels after liver transplantation. Infection 35 (2007) 346-351
41. Fortun J, Martín Dávila P, Alvarez ME, et al. Aspergillus galactomannan antigen in liver transplant recipients (LTR): a high false-positive rate in serum samples obtained during the first week post transplantation. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17-20 September 2007; Chicago, IL. Washington, DC: ASM Press. Abstract K-2167.